Fenwick Represents Augmedix in $23 Million Financing

December 08, 2016


Fenwick & West represented Augmedix, a leading smartglass-based physician productivity platform, in its $23 million strategic round of funding. Participants in the round included new investors McKesson Ventures and OrbiMed along with the company's existing institutional investors, Redmile Group, Emergence Capital and DCM Ventures.

The company will use the funds to further scale its service nationwide and to build out its platform with tools and services that drive improvements in physician productivity and patient care. More information about Augmedix’s $23 million financing can be obtained from the company press release.

The Fenwick transaction team was led by corporate lawyers Michael Esquivel, Malcolm Katz, Nam Kim and Elizabeth Chang; technology transactions lawyer Stefano Quintini; and executive compensation and employee benefits lawyer Shawn Lampron. ​